The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Resources for

Your office & patients

SUPPORT FOR YOUR OFFICE SO PATIENTS

CAN GET TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

Ready to enroll your patient in Skyrizi Complete and start the process?

BILLING AND CODING

Clear guidance on billing and coding for SKYRIZI, including NDC codes.

 

ACCESS AND REIMBURSEMENT

Forms and instructions to help patients with access and coverage.

 

SPECIALTY PHARMACIES

Contact details for specialty pharmacies

 

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

 

SKYRIZI COMPLETE ENROLLMENT

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

  • Download and fill out the Skyrizi Complete Enrollment and Prescription form with your patient
  • After submitting the form via fax, your patient will receive a call from a Nurse Ambassador*
  • You may also complete the Pharmacy Prescription Form and fax it to your patient's specialty pharmacy

ACCESS GUIDE

Get helpful access information for new SKYRIZI patients, including information on Access Specialists, Dosing, and Skyrizi Complete Enrollment and Prescription forms.

PRIOR AUTHORIZATION INSTRUCTIONS

Follow this helpful checklist to request coverage of SKYRIZI.

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

BILLING AND CODING

GUIDE TO BILLING AND CODING

Your guide to relevant codes (including commercial and Medicare) as well as helpful tips for completing forms.

NDC CODES

SKYRIZI

Pen

150 mg/mL

0074-2100-01

Carton of 1

SKYRIZI

Prefilled Syringe

150 mg/mL

0074-1050-01

Carton of 1

ACCESS AND REIMBURSEMENT FORMS

Along with support from Skyrizi Complete, you can use the forms here to help patients with access and coverage for SKYRIZI.

APPEALS LETTER SAMPLE

Appeal a denied claim for SKYRIZI.

FORMULARY EXCEPTION LETTER

Request a formulary exception to allow coverage for SKYRIZI.

HIPAA AUTHORIZATION

Allow patients to authorize the release of health information related to their treatment with SKYRIZI.

LETTER OF MEDICAL NECESSITY

Establish the medical necessity of SKYRIZI.

TIERED EXCEPTION LETTER

Request lower cost sharing for SKYRIZI as a preferred medication.

For support in person or over the phone, call your Access Specialist at 1-877-COMPLETE (1-877-266-7538)(1-877-266-7538)

SPECIALTY PHARMACIES

CONTACT DETAILS FOR SPECIALTY PHARMACIES

A complete list of specialty pharmacies that provide product-specific support for SKYRIZI.

Use these guides & best practices to help
get patients timely access to SKYRIZI

SKYRIZI ONBOARDING

ADDITIONAL RESOURCES

INJECTION SUPPORT VIDEOS

Injection Training Quick Tips

The resources on this page are provided for informational purposes only and are not intended as reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

SKYRIZI ONBOARDING

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Download and fill out the Skyrizi Complete Enrollment and Prescription form with your patient. After submitting the form via fax, your patient will receive a call from a Nurse Ambassador.* You may also complete the Pharmacy Prescription Form and fax it to your patient's specialty pharmacy.

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP).
They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

ADDITIONAL RESOURCES

BENEFITS VERIFICATION CHART

Help patients confirm their insurance coverage and out-of-pocket costs.

INSURANCE COMPARISON

Simple steps to help patients choose their insurance coverage when it's time to pick a plan.

INJECTION SUPPORT VIDEOS

A patient-friendly video with instructions on the full process of injecting SKYRIZI.

150 mg/mL SKYRIZI PEN

150 mg/mL PREFILLED SYRINGE

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference these videos for additional injection support.

INJECTION TRAINING QUICK TIPS

A quick-tip guide for patients on how to inject, whether they have injected before or are new to it. 

150 mg/mL SKYRIZI PEN

150 mg/mL PREFILLED SYRINGE

DOSING CONSIDERATIONS1:

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.

looking for more resources?Offer enrollment to patients and submit forms
electronically with CompletePro.com

By registering through CompletePro.com, you can choose the
capabilities that are most relevant to you and your patients’ needs, such as:

Instant benefits verification:

  • Patient out-of-pocket costs
  • Any prior authorization requirements
  • Pharmacy options available to the patient
  • Patient eligibility for any drug discount from the pharmaceutical company

Online prescribing efficiencies:

  • Complete a prior authorization and send it directly to the insurer
  • Send a prescription directly to the patient's chosen pharmacy
  • Send Skyrizi Complete Savings Card to your patient's preferred specialty pharmacy (with or without a prescription)
  • Be notified via text, email, or website in advance of patient's prior authorization expiration
  • Easily access each patient's prescription fill status

Stay up to date on the latest SKYRIZI news and information


4 DOSES PER YEAR

4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

ACR20/50/70 RESPONSE RATES

In patients with PsA at Week 24 and ~4 years1-3

Primary endpoint ACR20 at 24 weeks1